Tek başına ya da multipl skleroz seyri sırasında ortaya çıkan tümefaktif demiyelinizan lezyonların klinik, radyolojik ve laboratuvar özelliklerinin değerlendirilmesi, uzun süreli retrospektif ve prospektif takip sonuçları
Evaluation of clinical, radiological and laboratory characteristics of tumefactive demyelinating lesions occurring alone or during the course of multiple sclerosis, long-term retrospective and prospective follow-up results
- Tez No: 715278
- Danışmanlar: PROF. DR. MEFKÜRE ERAKSOY
- Tez Türü: Tıpta Uzmanlık
- Konular: Nöroloji, Neurology
- Anahtar Kelimeler: tumefactive demyelinating lesion, multiple sclerosis, tumefactive multiple sclerosis, tumor-like lesion
- Yıl: 2022
- Dil: Türkçe
- Üniversite: İstanbul Üniversitesi
- Enstitü: Tıp Fakültesi
- Ana Bilim Dalı: Nöroloji Ana Bilim Dalı
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 114
Özet
Giriş ve Amaç: Tümefaktif demiyelinizan lezyonlar (TDL), enflamatuar demiyelinizan hastalıklar spektrumunun bir varyantıdır. Tek başına ya da multipl skleroz (MS) seyri sırasında ortaya çıkabilir. Literatürde“demiyelinizan psödotümör”,“tümefaktif MS”,“tümör benzeri MS”,“tümör benzeri demiyelinizan lezyon”isimleri kullanılmıştır. Atipik klinik ve radyolojik bulguları olan, atipik seyirli olan ve MS'in immünmodülatör tedavilerine kısmi yanıt gösteren bu hastalarda atipik demiyelinizan sendromları ya da MS dışındaki tanıları düşünmek gerekir. Prevalansı MS vakalarının %1,4-8,2'si olarak bildirilmiştir. En sık başlangıç şekli polisemptomatik, motor ve duysal bulgular olmakla birlikte ensefalopati, nöbet, hemiparezi, ihmal gibi kortikal sendromlar ile başlayabilir. Lezyonlar, 2 cm'den büyük, sıklıkla frontal ve pariyetal lob yerleşimli, ödem ve kitle etkisi görülebilen, açık halka şeklinde kontrast tutulumu gösteren demiyelinizan özelliktedir. Klinik tablo, akut ya da subakut, hafif-orta ya da ciddi nörolojik bulgularla ortaya çıkabilir; bu belirti ve bulgular lezyonun bulunduğu lokalizasyona göre değişkendir. Merkezi Sinir Sistemi (MSS) neoplazmları, metastaz, abse, vaskülit ve granülomatoz hastalıklar ile ayırıcı tanısı yapılmalıdır. TDL'ler genel olarak, intravenöz metilprednizolon (IVMP) tedavisine yanıtlıdır ve McDonald MS kriterlerini karşılayan hastalar için hastalık seyrini değiştirmeye yönelik tedavilerin erken başlanması önemlidir. TDL'ler monofazik seyir gösterse de, %30-60'ında MS geliştiği bildirilmiştir ve sekonder progresyon nadirdir. Çalışmamızın amacı, nöroloji pratiğinde karşımıza çıkan, Manyetik Rezonans görüntülelemerde (MRG) saptanan tümör benzeri enflamatuar demiyelinizan lezyonların demografik, klinik ve radyolojik özelliklerini tanımlamak, tanı için klinisyenlerin faydalanacağı bilgiler elde etmek, hastalar için erken, hızlı ve doğru tedavi yaklaşımlarını belirlemek, hasta ve yakınları için yaşam planlarına ilişkin doğru prognoz ve akıbet bilgilerini verebilmek amaçlanmıştır. Bu bilgilerle, akut ve uzun dönem tedavi
Özet (Çeviri)
Introduction: Tumefactive demyelinating lesions (TDL) are a variant of the spectrum of inflammatory demyelinating diseases. It can occur alone or during the course of multiple sclerosis (MS). In the literature, the terms“demyelinating pseudotumor”,“tumefactive MS”,“tumor-like MS”,“tumor-like demyelinating lesion”have been used. Atypical demyelinating syndromes or diagnoses other than MS should be considered in these patients with atypical clinical and radiological findings, an atypical course, and a partial response to immunomodulatory treatments of MS. Prevalence of TDLs has been reported as 1.4-8.2% of MS cases. Although the most common initial clinic is polysymptomatic, motor, and sensory findings, it may occur with cortical syndromes such as encephalopathy, seizure, hemiparesis, neglect. TDLs are larger than 2 cm, often located in the frontal and parietal lobes, edema and mass effect can be seen, and open ring-shaped contrast enhancement. Their clinic might be moderate to severe, depending on the localization of the lesion. Differential diagnosis should be made with Central Nervous System (CNS) neoplasms, metastasis, abscess, vasculitis, and granulomatous diseases. For patients who are responsive to intravenous methylprednisolone (IVMP) therapy and fulfilled the McDonald's MS criteria, early initiation of disease modifying therapies (DMTs) is important. Although TDLs have a monophasic course, it has been reported that 30-60% of the patients develop multiple sclerosis, and secondary progression is rare. The aim of our study is to determine the demographic, clinical and radiological features of tumor-like lesions, and to obtain information that clinicians use for diagnosis. Therefore, we try to classify into subgroups and to help develop algorithms. In addition, we aimed to contribute to acute and long-term treatment approaches and patient management. 5 Patients and Methods: Clinical, imaging and laboratory characteristics, treatment responses and Expanded Disease Status Scale (EDSS) scores of 41 patients with TDL and MS followed up in our clinic (1981-2021) were retrospectively analyzed. Results: Thirty (73.2%) of the patients were female and 11 (26.8) were male. Ten (24%) of the patients had childhood-onset and 3 of thepatients (7%) were older than 50. The mean age at onset was 26.9±13.8 years. The mean follow-up period was 9.5±6.5 years. According to the disease features, there were 29 (70.7%) patients who occured with TDL alone and 12 (29.3%) patients who developed TDL during the course of MS. The most common initial findings were motor and sensorimotor findings. Oligoclonal bands (OCB) were detected in 42.4% (n=14). Localizations of the lesions were most frequently in the frontal and parietal lobes. The lesion size of 85.4% of TDLs was between 20-40 mm. T2 hypointense rim was seen in 48.6% of TDLs, 51% had heterogeneous, and 34.1% had open-ring contrast enhancement. Ten (34%) of 29 patients who occured with TDL alone were diagnosed with definitive MS in a median of 20 months (7-24 months). Eight patients (27%) remained monophasic during the follow-up period. Seven of the patients (24%) met the McDonald criteria, and were diagnosed with MS at initial MRI. Two patients (6%) were diagnosed with relapsing-remitting tumefactive lesions, while 1 patient (3%) was diagnosed with neuromyelitis optica (NMO) and 1 patient (3%) with myelin oligodendrocyte glycoprotein (MOG) associated disease. Among the recent diagnoses, the highest rate was relapsing relapsing MS (RMS) (75%). The median disease duration of patients with childhood-onset was significantly longer than adults (16, 7, p=0.006). The median of the initial and final EDSS were 3.0 (2.0-3.5) and 2.0 (1.0-2.7), respectively. The median final EDSS value of the patients with childhood onset was 2.2 (1-6) and the patients with adult onset were 2 (0-6) and were statistically similar (p=0.37). The median disease duration of the patients with monophasic course was longer (10.5, 6, p=0.014). Although the initial EDSS were similar, the median final EDSS in patients with a monophasic course was found to be significantly lower than in patients with a relapsingremitting course (1, 2, p=0.007). The median delta-EDSS of monophasic patients was significantly higher than the patients with a relapsing-remitting course (-1.5, -0.5, p=0.007). While 4 (9.8%) of the patients were being followed without treatment, 6 (14.6%) were using azathioprine and the others were receiving DMTs. The median of 6 final EDSS of the patients was 2 (1-2.7). The final EDSS of those receiving second-line DMT were similar. Conclusion: Tumefactive demyelinating diseases are a spectrum of inflammatory demyelinating diseases with characteristic radiological findings, which is more common than it is known towadays, and which is important to distinguish from malignancies in the differential diagnosis. TDL can occur alone or during the course of MS, and we found that these patients have a better prognosis than patients with RMS. This finding suggests that there might be a self-limiting feature of the disease. In our study, DMTs were initiated in the early period for the patients that have RMS, relapsing tumefactive MS, relapsing tumefactive demyelinating disease, and monophasic tumefactive demyelinating disease, who fulfilled the criteria for dissemination in time and space from the beginning. We concluded that the outcome of the patients who received first and second-line treatments was similar at the last EDSS, and that initiating high-level treatment in the early period was effective in modifying the course of the disease. Multicenter, larger, prospective, long-term studies of patients would be most informative and helpful for a better understanding of these clinical manifestations.
Benzer Tezler
- Mobil telefon kullanımına bağlı oluşan 900-1800 mhz radyo frekans dalgalarının meydana getirdiği elektromanyetik alanın iliak kanat kemik mineral yoğunluğuna etkisi
The effect of electromagnetic fields on bone mineral density of iliac bone produced by 900-1800 mhz radio frequency waves dependent on cellular phone usage
BEŞİR ANDAÇ AKSOY
Tıpta Uzmanlık
Türkçe
2006
Ortopedi ve TravmatolojiSüleyman Demirel ÜniversitesiOrtopedi ve Travmatoloji Ana Bilim Dalı
PROF.DR. NEVRES HÜRRİYET AYDOĞAN
- Multipl skleroz ve başağrısı
Multiple sclerosis and headache
GÖKHAN ÖZER
Tıpta Uzmanlık
Türkçe
2005
NörolojiSağlık BakanlığıNöroloji Ana Bilim Dalı
PROF. DR. UFUK ERGÜN
PROF. DR. LEVENT ERTUĞRUL İNAN
- Metilsülfonilmetan, glukozamin ve kondroitin sülfatın LPS/IFN-? ile uyarılmış RAW 264.7 makrofaj hücrelerinde apoptoz üzerine etkileri
Effects of methylsulfonylmethane, glucosamine and chondroitin sulfate on apoptosis in LPS/IFN-? stimulated RAW 264.7 macrophage cells
ARZU ZEYNEP KARABAY
- Ailesel multiple skleroz hastalarında genetik etiyolojinin araştırılması
Investigation of genetic etiology in familial multiple sclerosis patients
GİZEM NUR İZGİ
Tıpta Uzmanlık
Türkçe
2024
Genetikİstanbul Üniversitesi-CerrahpaşaTıbbi Genetik Ana Bilim Dalı
DOÇ. DR. ESRA ARSLAN ATEŞ